TY - JOUR
T1 - A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin
AU - al-Swayeh, O A
AU - Clifford, R H
AU - del Soldato, P
AU - Moore, P K
PY - 2000
Y1 - 2000
N2 - 1 Nitroaspirin (2.5-50 mg kg(-1), i.p. or 2.5-100 mg kg(-1), p.o.) and aspirin (2.5-100 mg kg(-1) i.p. or p.o.) exhibit anti-inflammatory activity in the carrageenan-induced hindpaw oedema model in the rat. When administered i.p., nitroaspirin was a more effective anti-oedema agent than aspirin particularly in the 'early' phase (i.e. up to 60 min) of the response. The ED50 values for nitroaspirin and aspirin as inhibitors of the 'late' phase response (measured at 180 min) were 64.3 mu mol kg(-1) and >555 mu mol kg(-1), respectively. When administered p.o., neither nitroaspirin nor aspirin exhibited significant anti-inflammatory activity in the 'early' phase and were of similar potency in the 'late' phase. Thus, at the highest dose used (100 mg kg(-1), 360 min) orally administered nitroaspirin (aspirin in parenthesis) inhibited oedema formation by 46.9 +/- 1.6% (47.2 +/- 3.8%, both n = 6, P <0.05). 2 Nitroaspirin and aspirin (25-200 mg kg(-1), p.o.) caused dose-related inhibition of the hyperalgesia to mechanical stimulation following intraplantar injection of carrageenan in the rat. ED50 values were 365 mu mol kg(-1) and 784 mu mol kg(-1), respectively. Neither drug influenced the threshold for mechanical stimulation in the contralateral (i.e. untreated) hindpaw. 3 Nitroaspirin and aspirin (2.5-100 mg kg(-1), p.o.) caused dose-related inhibition of acetic acid induced abdominal constrictions in the mouse (ED50 values of 154.7 mu mol kg(-1) and 242.8 mu mol kg(-1), respectively). 4 Nitroaspirin and aspirin (> 200 mg kg(-1), p.o.) reduced the 'late' phase (but not the 'early' phase) of the formalin-induced hindpaw licking assay in the mouse. Similarly, nitroaspirin and aspirin (> 50 mg kg(-1), p.o.) prolonged tail withdrawal latency following application of a noxious heat stimulus in the mouse.
AB - 1 Nitroaspirin (2.5-50 mg kg(-1), i.p. or 2.5-100 mg kg(-1), p.o.) and aspirin (2.5-100 mg kg(-1) i.p. or p.o.) exhibit anti-inflammatory activity in the carrageenan-induced hindpaw oedema model in the rat. When administered i.p., nitroaspirin was a more effective anti-oedema agent than aspirin particularly in the 'early' phase (i.e. up to 60 min) of the response. The ED50 values for nitroaspirin and aspirin as inhibitors of the 'late' phase response (measured at 180 min) were 64.3 mu mol kg(-1) and >555 mu mol kg(-1), respectively. When administered p.o., neither nitroaspirin nor aspirin exhibited significant anti-inflammatory activity in the 'early' phase and were of similar potency in the 'late' phase. Thus, at the highest dose used (100 mg kg(-1), 360 min) orally administered nitroaspirin (aspirin in parenthesis) inhibited oedema formation by 46.9 +/- 1.6% (47.2 +/- 3.8%, both n = 6, P <0.05). 2 Nitroaspirin and aspirin (25-200 mg kg(-1), p.o.) caused dose-related inhibition of the hyperalgesia to mechanical stimulation following intraplantar injection of carrageenan in the rat. ED50 values were 365 mu mol kg(-1) and 784 mu mol kg(-1), respectively. Neither drug influenced the threshold for mechanical stimulation in the contralateral (i.e. untreated) hindpaw. 3 Nitroaspirin and aspirin (2.5-100 mg kg(-1), p.o.) caused dose-related inhibition of acetic acid induced abdominal constrictions in the mouse (ED50 values of 154.7 mu mol kg(-1) and 242.8 mu mol kg(-1), respectively). 4 Nitroaspirin and aspirin (> 200 mg kg(-1), p.o.) reduced the 'late' phase (but not the 'early' phase) of the formalin-induced hindpaw licking assay in the mouse. Similarly, nitroaspirin and aspirin (> 50 mg kg(-1), p.o.) prolonged tail withdrawal latency following application of a noxious heat stimulus in the mouse.
UR - http://www.scopus.com/inward/record.url?scp=0033960353&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0703064
DO - 10.1038/sj.bjp.0703064
M3 - Article
SN - 1476-5381
VL - 129
SP - 343
EP - 350
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 2
ER -